Bioxodes

🚀 Bioxodes today updates investors about its latest business news! ✅ We’ve secured an additional €2.7 million from existing investors, in an extension of our Series A funding, which now totals around €15 million.  This will enable us to reach our milestones for 2025 and to start our Series B funding round, of roughly €50 million, in the second quarter. ✅ Clinical progress: We expect to have interim data from the first 16 patients in the Phase 2a trial for BIOX-101 this quarter. Recruitment is ongoing for up to 16 additional patients. Preparations are in full swing for an international Phase 2b study with BIOX-101, which we are planning to launch early next year. We’re making great strides, and we appreciate the continued support! 🙌 📢 Read our full press release here 👉 https://lnkd.in/eqANwx_X #Biotech #FundingNews #SeriesA #SeriesBFunding #ClinicalTrials #BIOX101 #Innovation #Healthcare #Investment #Pharma

🚀 Bioxodes today updates investors about its latest business news! ✅ We’ve secured an additional €2.7 million from existing investors, in an extension of our Series A funding, which now totals around €15 million.  This will enable us to reach our milestones for 2025 and to start our Series B funding round, of roughly €50 million, in the second quarter. ✅ Clinical progress: We expect to have interim data from the first 16 patients in the Phase 2a trial for BIOX-101 this quarter. Recruitment is ongoing for up to 16 additional patients. Preparations are in full swing for an international Phase 2b study with BIOX-101, which we are planning to launch early next year. We’re making great strides, and we appreciate the continued support! 🙌 📢 Read our full press release here 👉 https://lnkd.in/eqANwx_X #Biotech #FundingNews #SeriesA #SeriesBFunding #ClinicalTrials #BIOX101 #Innovation #Healthcare #Investment #Pharma

🌟 Exciting news from #ISC2025! 🌟 Yesterday, our colleague Valérie Pireaux presented a poster on BIOX-101 (Ir-CPI) in a preclinical intracerebral hemorrhage model at the International Stroke Conference 2025. It was a fantastic opportunity to showcase our latest research and engage in discussions with experts in the field. Thank you to everyone who stopped by to learn more and share insights! Looking forward to more collaborations and advancements in stroke research. Check here for the abstract and poster 👉 https://lnkd.in/eWCMJt2j #Neuroscience #PreclinicalResearch #BIOX101 #Stroke #Teamwork #biotech #ISC2025

🚀 Exciting News! 🚀 Our colleague Valérie Pireaux, Preclinical Scientist, is within the starting blocks for ISC 2025! 🏁 She will be representing Bioxodes and presenting our cutting-edge preclinical research on BIOX-101 for intracerebral hemorrhage, paving the way for innovation in stroke treatment. Stay tuned for insights and breakthroughs as we contribute to advancing the field! 💡🧠 https://lnkd.in/eWCMJt2j #ISC2025 #StrokeResearch #Neuroscience #IntracerebralHemorrhage #Innovation #Teamwork

🌟 Bioxodes at ISC 2025 – Driving Innovation in Stroke Care 🌟 We’re excited to announce that Bioxodes will attend the International Stroke Conference 2025 from February 5–7 at the Los Angeles Convention Center! Our Preclinical Scientist, Valérie Pireaux, will present a poster with the latest preclinical data on BIOX-101, showcasing its potential in addressing intracerebral hemorrhage — a critical area of unmet medical need. This is a pivotal moment for Bioxodes as we continue to advance our innovative pipeline and demonstrate our commitment to improving outcomes for patients. Stay tuned for updates, and let’s connect at ISC 2025! 🚀 More info here 👉 https://lnkd.in/ewFpAwG4 #StrokeCare #Innovation #Bioxodes #ISC2025 #HealthcareInvesting

Wishing you all a joyful holiday season from the entire Bioxodes team! 🎄 We are incredibly grateful for your support and the progress we've made together this past year. We eagerly anticipate what 2025 has in store for us! #bioxodes #christmas2024 #biotech #stroke #clinicaldevelopment

✨ Bioxodes meets a milestone – 16th patient enrolled in BIOX-101 trial. ✨ Bioxodes has enrolled patient nr 16 in a clinical trial with BIOX-101 in hemorrhagic stroke, marking a major milestone that will trigger an interim data analysis. Across 10 stroke units in Belgium, we are testing BIOX-101, a therapy designed to limit the damage from intracerebral hemorrhagic stroke (ICH), developed from tick saliva. ICH is an often deadly disease for which there is no available medication. It causes some 40% of all stroke-related deaths, even though it makes up only 13% of all strokes. We expect our interim report by March 2025, an important next step in our mission of offering a breakthrough hope for hemorrhagic stroke patients. Full press release 👉 https://lnkd.in/d_rW9auU BioWin Brussels South Charleroi BioPark #strokecare #voiceofstroke #clinicaltrials #biotech #healthcare #innovation

🔺 MEDIA ARTICLE 🔻 Promising advancements in the treatment of hemorrhagic stroke An insightful interview with our CMO Hans Warrinnier was recently featured in Doctissimo.fr, where journalist Magali Régnier-Ratuvou explored the groundbreaking potential of BIOX-101 for hemorrhagic stroke. This article sheds light on the urgent need for innovative treatments for this life-threatening condition and how BIOX-101 could help minimize long-term damage and improve outcomes for patients. 🧠 Derived from the saliva of ticks, #BIOX-101 combines anti-clotting and anti-inflammatory properties without increasing the risk of bleeding—a critical advantage in stroke management. As shared in the interview, Bioxodes is paving the way for a new therapeutic era, with its current Phase 2a trial already underway across 10 specialized stroke centers in Belgium.  A special thank you to Magali Régnier-Ratuvou and the Doctissimo.fr team for the thoughtful and engaging collaboration on this article. It’s a privilege to share Bioxodes’ mission and innovations with a wider audience. 📌 Read the full article here (in French) 👉 https://lnkd.in/euwQE3EU 📌 Learn more about Bioxodes and their mission 👉 www.bioxodes.com #Biotech #Innovation #StrokeTreatment #LifeSciences #strokecare

🤔 Curious about how a tick molecule can potentially rescue lives after a hemorrhagic stroke? 🧠 Discover our poster explaining the mode of action of our lead drug candidate BIOX-101, the potential impact and key findings in a ICH mouse model. We are still at the Brain Innovation Days today for more insights. Not in Brussels today? Head over to our website for more information 👉 bioxodes.com Poster credits to Stéphanie Demoulin, Valérie Pireaux, Marc Dechamps, Hans Warrinnier, Edmond Godfroid #strokecare #voiceofstroke #braininnovationdays #clinicaltrials

🌟 Full house at the Brain Innovation Days in Brussels! We are thrilled to announce that our Chief Medical Officer, Dr. Hans Warrinnier, had the honor of delivering an elevator pitch, presenting the groundbreaking potential of BIOX-101 to investors and key stakeholders. Being chosen to pitch among a select group is a true privilege, reflecting the significance of the unmet medical need we’re addressing. BIOX-101 is our unique therapeutic solution designed to tackle critical gaps in patient care. With a clear focus on addressing challenging medical conditions where there are limited or no existing treatments, BIOX-101 represents hope for patients and healthcare providers alike. In addition to the pitch, we are proud to share that Bioxodes was also selected to showcase a poster at the conference, highlighting our recent developments. Our CEO, Marc Dechamps, and CMO, Dr. Hans Warrinnier, are onsite today and tomorrow to engage with attendees and discuss the science and strategy behind our innovation. We look forward to sharing more about our journey to advance neurological health and are grateful to #BrainInnovationDays for this opportunity. #HealthcareInnovation #Biotech #StrokeCare #BIOX101 #Bioxodes #BrainHealth